Advertisement

Meta-Analysis Comparison (Nine Trials) of Outcomes With Drug-Eluting Stents Versus Bare Metal Stents in Patients With Diabetes Mellitus

Published:September 09, 2008DOI:https://doi.org/10.1016/j.amjcard.2008.07.012
      In patients with diabetes mellitus, outcome after drug-eluting stent (DES) versus bare metal stent (BMS) implantation remains under investigation; although lower reintervention rates were reported, incidence of death and myocardial infarction (MI) during follow-up is not completely characterized. Thus, we performed a meta-analysis of available randomized studies evaluating follow-up events of DESs versus BMSs in patients with diabetes mellitus. Randomized trials reporting outcome of DES versus BMS in diabetic patients with a follow-up ≥6 months were included. Outcomes analyzed were (1) death, (2) MI, (3) in-stent restenosis (ISR) and target lesion revascularization (TLR), and (4) stent thrombosis. Data were extracted by 2 independent reviewers. A total of 9 trials, including 1,141 patients, were found. ISR occurred in 8% of patients with DESs versus 41% of those with BMSs (odds ratio [OR] 0.13, 95 confidence interval [CI] 0.09 to 0.20, p <0.00001) and TLR in 8% versus 27% (OR 0.23, 95% CI 0.16 to 0.33, p <0.00001). There was no difference in the incidence of stent thrombosis (1.1% vs 1.2%, p = 0.98) or death (2.4% vs 2.3%, p = 0.91). MI occurred in 3.5% of patients with DESs versus 7.2% of those with BMSs (52% risk decrease, p = 0.02). Decrease of ISR with DESs was observed in noninsulin-treated (OR 0.17, 95% CI 0.11 to 0.26, p <0.00001) and insulin-treated (OR 0.22, 95% CI 0.13 to 0.37, p <0.00001) patients. In conclusion, diabetic patients receiving DESs have lower risk of ISR and TLR versus those treated with BMSs; use of DESs in patients with diabetes mellitus significantly decreases the incidence of MI during follow-up, without affecting mortality or stent thrombosis.
      To read this article in full you will need to make a payment

      References

        • Mauri L.
        • Hsieh W.H.
        • Massaro J.M.
        • Ho K.K.
        • D'Agostino R.
        • Cutlip D.E.
        Stent thrombosis in randomized clinical trials of drug-eluting stents.
        N Engl J Med. 2007; 356: 1020-1029
      1. Higgins J.P.T. Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 Updated May 2005. The Cochrane Library, Issue 3. John Wiley & Sons, Chichester, UK2005 (Available at: http://www.cochrane.org/resources/handbook/hbook.htm. Accessed 2008.)
        • Altman D.G.
        • Schulz K.F.
        Statistics notes: concealing treatment allocation in randomized trials.
        BMJ. 2001; 323: 446-447
        • Juni P.
        • Witschi A.
        • Bloch R.
        • Egger M.
        The hazards of scoring the quality of clinical trials for meta-analysis.
        JAMA. 1999; 282: 1054-1060
        • Sabate M.
        • Jimenez-Quevedo P.
        • Angiolillo D.J.
        • Gomez-Hospital J.A.
        • Alfonso F.
        • Hernandez-Antolin R.
        • Goicolea J.
        • Banuelos C.
        • Escaned J.
        • Moreno R.
        • et al.
        • DIABETES Investigators
        Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the Diabetes and Sirolimus-Eluting Stent (DIABETES) trial.
        Circulation. 2005; 112: 2175-2183
        • Morice M.C.
        • Serruys P.W.
        • Sousa J.E.
        • Fajadet J.
        • Ban Hayashi E.
        • Perin M.
        • Colombo A.
        • Schuler G.
        • Barragan P.
        • Guagliumi G.
        • Molnar F.
        • Falotico R.
        • RAVEL Study Group
        Randomized study with the sirolimus-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions.
        N Engl J Med. 2002; 346: 1773-1780
        • Colombo A.
        • Drzewiecki J.
        • Banning A.
        • Grube E.
        • Hauptmann K.
        • Silber S.
        • Dudek D.
        • Fort S.
        • Schiele F.
        • Zmudka K.
        • Guagliumi G.
        • Russell M.E.
        • TAXUS II Study Group
        Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions.
        Circulation. 2003; 108: 788-794
        • Moses J.W.
        • Leon M.B.
        • Popma J.J.
        • Fitzgerald P.J.
        • Holmes D.R.
        • O'Shaughnessy C.
        • Caputo R.P.
        • Kereiakes D.J.
        • Williams D.O.
        • Teirstein P.S.
        • Jaeger J.L.
        • Kuntz R.E.
        • SIRIUS Investigators
        Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.
        N Engl J Med. 2003; 349: 1315-1323
        • Schofer J.
        • Schluter M.
        • Gershlick A.H.
        • Wijns W.
        • Garcia E.
        • Schampaert E.
        • Breithardt G.
        • E-SIRIUS Investigators
        Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS).
        Lancet. 2003; 362: 1093-1099
        • Schampaert E.
        • Cohen E.A.
        • Schluter M.
        • Reeves F.
        • Traboulsi M.
        • Title L.M.
        • Kuntz R.E.
        • Popma J.J.
        • C-SIRIUS Investigators
        The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS).
        J Am Coll Cardiol. 2004; 43: 1110-1115
        • Stone G.W.
        • Ellis S.G.
        • Cox D.A.
        • Hermiller J.
        • O'Shaughnessy C.
        • Mann J.T.
        • Turco M.
        • Caputo R.
        • Bergin P.
        • Greenberg J.
        • Popma J.J.
        • Russell M.E.
        • TAXUS-IV Investigators
        A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
        N Engl J Med. 2004; 350: 221-231
        • Ardissino D.
        • Cavallini C.
        • Bramucci E.
        • Indolfi C.
        • Marzocchi A.
        • Manari A.
        • Angeloni G.
        • Carosio G.
        • Bonizzoni E.
        • Colusso S.
        • Repetto M.
        • Merlini P.A.
        • SES-SMART Investigators
        Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial.
        JAMA. 2004; 292: 2727-2734
        • Dawkins K.D.
        • Grube E.
        • Guagliumi G.
        • Banning A.P.
        • Zmudka K.
        • Colombo A.
        • Thuesen L.
        • Hauptman K.
        • Marco J.
        • Wijns W.
        • et al.
        • TAXUS VI Investigators
        Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice.
        Circulation. 2005; 112: 3306-3313
        • Stone G.W.
        • Moses J.W.
        • Ellis S.G.
        • Schofer J.
        • Dawkins K.D.
        • Morice M.C.
        • Colombo A.
        • Schampaert E.
        • Grube E.
        • Kirtane A.J.
        • et al.
        Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
        N Engl J Med. 2007; 356: 998-1008
        • Kastrati A.
        • Mehilli J.
        • Pache J.
        • Kaiser C.
        • Valgimigli M.
        • Kelbaek H.
        • Menichelli M.
        • Sabaté M.
        • Suttorp M.J.
        • Baumgart D.
        • et al.
        Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.
        N Engl J Med. 2007; 356: 1030-1039
        • Patti G.
        • Pasceri V.
        • Melfi R.
        • Goffredo C.
        • Chello M.
        • D'Ambrosio A.
        • Montesanti R.
        • Di Sciascio G.
        Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation.
        Circulation. 2005; 111: 70-75
        • Aronson D.
        • Bloomgarden Z.
        • Rayfield E.J.
        Potential mechanisms promoting restenosis in diabetic patients.
        J Am Coll Cardiol. 1996; 27: 528-535
        • Carrozza Jr, J.P.
        • Kuntz R.E.
        • Fishman R.F.
        • Baim D.S.
        Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus.
        Ann Intern Med. 1993; 118: 344-349
        • Di Sciascio G.
        • Patti G.
        • Nasso G.
        • Manzoli A.
        • D'Ambrosio A.
        • Abbate A.
        Early and long-term results of stenting of diffuse coronary artery disease.
        Am J Cardiol. 2000; 86: 1166-1170
        • Boyden T.F.
        • Nallamothu B.K.
        • Moscucci M.
        • Chan P.S.
        • Grossman P.M.
        • Tsai T.T.
        • Chetcuti S.J.
        • Bates E.R.
        • Gurm H.S.
        Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus.
        Am J Cardiol. 2007; 99: 1399-1402
        • Elezi S.
        • Kastrati A.
        • Pache J.
        • Wehinger A.
        • Hadamitzky M.
        • Dirschinger J.
        • Neumann F.J.
        • Schomig A.
        Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement.
        J Am Coll Cardiol. 1998; 32: 1866-1873
        • Moreno R.
        • Fernandez C.
        • Calvo L.
        • Sanchez-Recalde A.
        • Galeote G.
        • Sanchez-Aquino R.
        • Alfonso F.
        • Macaya C.
        • Lopez-Sendon J.L.
        Meta-analysis comparing the effect of drug-eluting versus bare metal stents on risk of acute myocardial infarction during follow-up.
        Am J Cardiol. 2007; 99: 621-625
        • Daemen J.
        • Garcia-Garcia H.M.
        • Kukreja N.
        • Imani F.
        • de Jaegere P.P.
        • Sianos G.
        • van Domburg R.T.
        • Serruys P.W.
        The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus.
        Eur Heart J. 2007; 28: 26-32
        • Spaulding C.
        • Daemen J.
        • Boersma E.
        • Cutlip D.E.
        • Serruys P.W.
        A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents.
        N Engl J Med. 2007; 356: 989-997
        • Jimenez-Quevedo P.
        • Sabatè M.
        • Angiolillo D.J.
        • Alfonso F.
        • Hernandez-Antolin R.
        • SanMartin M.
        • Gomez-Hospital J.A.
        • Banuelos C.
        • Escaned J.
        • Moreno R.
        • et al.
        Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
        Eur Heart J. 2007; 28: 1946-1952
        • Kirtane A.J.
        • Ellis S.G.
        • Dawkins K.D.
        • Colombo A.
        • Grube E.
        • Popma J.J.
        • Fahy M.
        • Leon M.B.
        • Moses J.W.
        • Mehran R.
        • Stone G.W.
        Paclitaxel-eluting coronary stents in patients with diabetes mellitus.
        J Am Coll Cardiol. 2008; 51: 708-715
        • Pfisterer M.
        • Brunner-La Rocca H.P.
        • Buser P.T.
        • Rickenbacher P.
        • Hunziker P.
        • Mueller C.
        • Jeger R.
        • Bader F.
        • Osswald S.
        • Kaiser C.
        • BASKET-LATE Investigators
        Late clinical events after clopidogrel discontinuation may limit the benefit of drug eluting stents: an observational study of drug-eluting versus bare-metal stents.
        J Am Coll Cardiol. 2006; 48: 2584-2591